Pharmacoeconomics of Pharmacogenetics within the Context of General Health Technology Assessments
Authors:
- Maarten J. PostmaMPMaarten J. Postma
- Cornelis BoersmaCBCornelis Boersma
- S. VegterSVS. Vegter
- Dominique VandijckDVDominique Vandijck
- L. AnnemansLAL. Annemans
- 1 January 2013
- book chapter
- Published by Elsevier
- p. 429-450
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Structured Self-Monitoring of Blood Glucose Significantly Reduces A1C Levels in Poorly Controlled, Noninsulin-Treated Type 2 DiabetesDiabetes Care, 2011
- Availability of and Access to Orphan DrugsPharmacoEconomics, 2011
- Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancerEuropean Journal of Cancer, 2010
- Constructive Technology Assessment (CTA) as a tool in Coverage with Evidence Development: The case of the 70-gene prognosis signature for breast cancer diagnosticsInternational Journal of Technology Assessment in Health Care, 2009
- Validation of 70-gene prognosis signature in node-negative breast cancerBreast Cancer Research and Treatment, 2008
- Public health economics of vaccines in the Netherlands: methodological issues and applicationsJournal of Public Health, 2008
- Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening ProgrammesPharmacoEconomics, 2008
- Impact of a 21‐gene RT‐PCR assay on treatment decisions in early‐stage breast cancerCancer, 2007
- A Decision Chart for Assessing and Improving the Transferability of Economic Evaluation Results Between CountriesPharmacoEconomics, 2004
- A Gene-Expression Signature as a Predictor of Survival in Breast CancerNew England Journal of Medicine, 2002